natgillin/translations-raw huggingface dataset:
Keppra contains methyl parahydroxybenzoate, propyl parahydroxybenzoate and maltitol Keppra oral solution includes methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed). 
Keppra sadrži metilparahidroksibenzoat, propilparahidroksibenzoat i maltitol Keppra 100 mg/ml oralna otopina sadrži metilparahidroksibenzoat (E218) i propilparahidroksibenzoat (E216) koji mogu izazvati alergijske reakcije (koje mogu biti i odgođene).
Keppra contains sodium 
Keppra sadrži natrij
• Dextrose 50 mg/ml (5%) solution for injection 
• otopina glukoze 50 mg/ml (5 %) za injekciju
The 300 ml glass bottle of Keppra (for children aged 4 years and above, adolescents and adults) is packed in a cardboard box containing a 10 ml oral syringe (graduated every 0.25 ml) and an adaptor for the syringe. 
Staklena boca od 300 ml Keppre (za djecu u dobi od 4 godine i stariju, adolescente i odrasle) pakirana je u kartonsku kutiju koja još sadrži štrcaljku za usta od 10 ml (s oznakom na svakih 0,25 ml) i nastavak za štrcaljku.
For children 6 months to 4 years, measure the appropriate dosage using the 3 ml syringe included in the package. 
Za djecu u dobi od 6 mjeseci do 4 godine, odmjerite odgovarajuću dozu koristeći štrcaljku od 3 ml koja je priložena u pakiranju.
Aluminium/PVC blister 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP Aluminij/PVC blister
Keppra 100 mg/ml oral solution Levetiracetam 
Keppra 100 mg/ml oralna otopina levetiracetam
The other ingredients are: Tablet core: croscarmellose sodium, macrogol 6000, silica colloidal anhydrous, magnesium stearate. 
Jezgra tablete: umrežena karmelozanatrij, makrogol 6000, bezvodni koloidni silicijev dioksid, magnezijev stearat.
Excipient with known effect: Each film-coated tablet contains 0.19 mg of sunset yellow FCF (E110). 
Jedna filmom obložena tableta sadrži 0,19 mg sunset yellow FCF (E110).
The CLcr in ml/min/1.73 m2 may be estimated from serum creatinine (mg/dl) determination, for young adolescents and children using the following formula (Schwartz formula): 
Klirens kreatinina u ml/min/1,73 m2 može se za mlade adolescente i djecu procijeniti iz vrijednosti serumskoga kreatinina (mg/dl) s pomoću sljedeće formule (Schwartzova formula):
Film-coating: Polyvinyl alcohol-part. hydrolyzed, titanium dioxide (E171), macrogol 3350, talc, colourants*. 
Film ovojnica: djelomično hidroliziran polivinilni alkohol, titanijev dioksid (E171), makrogol 3350, talk, bojila*.
How to take Keppra 
Kako uzimati Keppru
Other ingredients include sodium acetate, glacial acetic acid, sodium chloride, water for injections. 
Ostale pomoćne tvari su natrijev acetat, ledena acetatna kiselina, natrijev klorid, voda za injekcije.
Sodium acetate Glacial acetic acid Sodium chloride Water for injections 
6.1 Popis pomoćnih tvari natrijev acetat acetatna kiselina, ledena natrijev klorid voda za injekcije
EU/1/00/146/026 200 tablets (2 packs of 100) EU/1/00/146/037 100 x 1 tablets 
EU/1/00/146/026 200 tableta (2 pakiranja od 100) EU/1/00/146/037 100 x 1 tableta
The NOAEL was ≥ 1800 mg/kg/day for the F0 females, and for the survival, growth and development of the F1 offspring up to weaning (x 6 the MRHD on a mg/m2 basis). 
NOAEL je iznosila ≥ 1800 mg/kg/dan za F0 ženke, te za preživljenje, rast i razvoj za F1 potomstvo do odbića (6-erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2).
• asthenia/fatigue (tiredness). 
• astenija /umor (zamaranje).
How to store Keppra 
Kako čuvati Keppru
Only use the 3 ml syringe included in the package. 
Koristite samo štrcaljku od 3 ml koja se nalazi u pakiranju.
Contact your doctor if you took more Keppra than you should. 
Obavijestite liječnika ako ste uzeli veću količinu Keppre nego što ste trebali.
UCB Pharma SA Allée de la Recherche 60 B-1070 Brussels Belgium 
UCB Pharma SA Allée de la Recherche 60 B-1070 Brussels BELGIJA
UCB Pharma SA Allée de la Recherche 60 B-1070 Brussels BELGIUM 
UCB Pharma SA Allée de la Recherche 60 B-1070 Brussels Belgija
For children above 4 years, measure the appropriate dosage using the 10 ml syringe included in the package. 
Za djecu u dobi iznad 4 godine, odmjerite odgovarajuću dozu koristeći štrcaljku od 10 ml koja je priložena u pakiranju.
If you stop taking Keppra: 
Ako prestanete uzimati Keppru
Only use the 10 ml syringe included in the package. 
Koristite samo štrcaljku od 10 ml koja se nalazi u pakiranju.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 
SADRŽAJ PO TEŽINI, VOLUMENU ILI DOZNOJ JEDINICI LIJEKA 500 mg/5 ml
44.6 % of the levetiracetam treated patients and 19.6 % of the patients on placebo had a 50 % or greater reduction from baseline in the partial onset seizure frequency per week. 
U 44,6% bolesnika liječenih levetiracetamom i 19,6% bolesnika koji su dobivali placebo zapaženo je 50 %-tno ili više smanjenje od početne učestalosti parcijalnih napadaja tjedno.
What you need to know before you are given Keppra 
Što morate znati prije nego počnete dobivati Keppru
Keppra is for intravenous use. 
Keppra se daje u venu.
Suicide attempt, suicidal ideation, psychotic disorder, abnormal behaviour, hallucination, anger, confusional state , panic attack, affect lability/mood swings, agitation 
Pokušaj samoubojstva, suicidalne misli, psihotični poremećaj, poremećaj ponašanja, halucinacije, srditost, konfuzno stanje, napadaj panike, labilnost afekta/promjene raspoloženja, agitacija
EU/1/00/146/028 200 tablets (2 packs of 100) EU/1/00/146/036 100 x 1 tablets 
EU/1/00/146/028 200 tableta (2 pakiranja od 100) EU/1/00/146/036 100 x 1 tableta
• skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (StevensJohnson syndrome), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis); 
jako rasprostranjen osip s mjehurma i kožom koja se ljušti, osobito oko usta, nosa, očiju i genitalija (Stevens-Johnsonov sindrom), i mnogo teži oblik koji uzrokuje ljuštenje kože na više od 30% površine tijela (toksična epidermalna nekroliza);
Keppra 100 mg/ml concentrate for solution for infusion Levetiracetam 
Keppra 100 mg/ml koncentrat za otopinu za infuziju levetiracetam
Keppra 100 mg/ml concentrate for solution for infusion 
NAZIV LIJEKA Keppra 100 mg/ml koncentrat za otopinu za infuziju
- A 150 ml bottle with a 3 ml oral syringe (delivering up to 300 mg levetiracetam) graduated every 0.1 ml (corresponding to 10 mg) 
- Boca od 150 ml sa štrcaljkom za usta od 3 ml (koja dostavlja do 300 mg levetiracetama) s podjelama po 0,1 ml (što odgovara količini od 10 mg).
EU/1/00/146/030 (polytetrafluoroethylene -faced stopper) EU/1/00/146/033 (Uncoated stopper) 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/00/146/030 (čep obložen politetrafluoroetilenom) EU/1/00/146/033 (neobložen čep)
- A 150 ml bottle with a 1 ml oral syringe (delivering up to 100 mg levetiracetam) graduated every 0.05 ml (corresponding to 5 mg) 
- Boca od 150 ml sa štrcaljkom za usta od 1 ml (koja dostavlja do 100 mg levetiracetama) s podjelama po 0,05 ml (što odgovara količini od 5 mg).
One tablet of Keppra 1,000 mg contains 1,000 mg of levetiracetam. 
Jedna tableta Keppre 1000 mg sadrži 1000 mg levetiracetama.
The 150 ml glass bottle of Keppra (for infants aged 1 month to less than 6 months) is packed in a cardboard box containing a 1 ml oral syringe (graduated every 0.05 ml) and an adaptor for the syringe. 
Staklena boca od 150 ml Keppre (za dojenčad u dobi od 1 mjeseca do manje od 6 mjeseci) pakirana je u kartonsku kutiju koja još sadrži štrcaljku za usta od 1 ml (s oznakom na svakih 0,05 ml) i nastavak za štrcaljku.
Depression, hostility/ aggression, anxiety, insomnia, nervousness/ irritability 
Depresija, netrpeljivost/ agresivnost, anksioznost, nesanica, nervoza/razdražljivost
EU/1/00/146/001 20 tablets EU/1/00/146/002 30 tablets EU/1/00/146/003 50 tablets EU/1/00/146/004 60 tablets EU/1/00/146/005 100 tablets EU/1/00/146/029 200 tablets (2 packs of 100) EU/1/00/146/034 100 x 1 tablets 
EU/1/00/146/001 20 tableta EU/1/00/146/002 30 tableta EU/1/00/146/003 50 tableta EU/1/00/146/004 60 tableta EU/1/00/146/005 100 tableta EU/1/00/146/029 200 tableta (2 pakiranja od 100) EU/1/00/146/034 100 x 1 tableta
500 mg/5 ml 
OBLIK I SADRŽAJ 500 mg/5 ml
EU/1/00/146/006 10 tablets EU/1/00/146/007 20 tablets EU/1/00/146/008 30 tablets EU/1/00/146/009 50 tablets EU/1/00/146/010 60 tablets EU/1/00/146/011 100 tablets EU/1/00/146/012 120 tablets EU/1/00/146/013 200 tablets (2 packs of 100) EU/1/00/146/035 100 x 1 tablets 
EU/1/00/146/006 10 tableta EU/1/00/146/007 20 tableta EU/1/00/146/008 30 tableta EU/1/00/146/009 50 tableta EU/1/00/146/010 60 tableta EU/1/00/146/011 100 tableta EU/1/00/146/012 120 tableta EU/1/00/146/013 200 tableta (2 pakiranja od 100) EU/1/00/146/035 100 x 1 tableta
Clear, colourless, liquid. 
Bistra, bezbojna tekućina.
The 150 ml glass bottle of Keppra (for infants and young children aged from 6 months to less than 4 years) is packed in a cardboard box containing a 3 ml oral syringe (graduated every 0.1 ml) and an adaptor for the syringe. 
Staklena boca od 150 ml Keppre (za dojenčad i malu djecu u dobi od 6 mjeseci do manje od 4 godine) pakirana je u kartonsku kutiju koja još sadrži štrcaljku za usta od 3 ml (s oznakom na svakih 0,1 ml) i nastavak za štrcaljku.
NextPharma SAS 
Oralna otopina NextPharma SAS
anger, confusion, panic attack, emotional instability/mood swings, agitation; 
halucinacije, srditost, smetenost, napadaj panike, emocionalna nestabilnost/promjene raspoloženja, uznemirenost;
Do not use this medicine after the expiry date stated on the carton box and blister after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru iza oznake „Rok valjanosti“ ili „EXP:“.
Keppra 750 mg film-coated tablets are orange, 18 mm oblong, scored and debossed with the code “ucb” and “750” on one side. 
Keppra 750 mg filmom obložene tablete su narančaste, duguljaste, od 18 mm s razdjelnom crtom i utisnutim oznakama „ucb“ i „750“ na jednoj strani.
With continued long-term treatment, 28.6 % of the patients were free of myoclonic seizures for at least 6 months and 21.0 % were free of myoclonic seizures for at least 1 year. 
S nastavkom dugotrajnog liječenja 28,6% bolesnika bilo je barem 6 mjeseci i 21,0% barem 1. godinu bez miokloničkih napadaja.
Keppra 1000 mg film-coated tablets are white, 19 mm oblong, scored and debossed with the code “ucb” and“1000” on one side. 
Keppra 1000 mg filmom obložene tablete su bijele, duguljaste, od 19 mm s razdjelnom crtom i utisnutim oznakama „ucb” i „1000“ na jednoj strani.
A 750 mg loading dose is recommended on the first day of treatment with levetiracetam. 
(1) Prvog dana liječenja levetiracetamom preporučuje se udarna doza od 750 mg.
Polyvinyl alcohol-part. hydrolyzed Titanium dioxide (E171) Macrogol 3350 
Film ovojnica polivinilni alkohol, djelomično hidroliziran titanijev dioksid (E171) makrogol 3350 talk
150 ml oral solution 
OBLIK I SADRŽAJ 150 ml oralna otopina
If levetiracetam has to be discontinued it is recommended to withdraw it gradually (e.g. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in infants older than 6 months, children and adolescents weighting less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks; in infants (less than 6 months): dose decrease should not exceed 7 mg/ kg twice daily every two weeks). 
Ako treba prekinuti liječenje levetiracetamom, preporučuje se postupni prekid (npr. u odraslih i adolescenata tjelesne težine veće od 50 kg: smanjenje za 500 mg dva puta na dan svaka dva do četiri tjedna; u dojenčadi starije od 6 mjeseci, djece i adolescenata tjelesne težine manje od 50 kg: smanjenje doze ne smije biti veće od 10 mg/kg dva puta na dan svaka dva tjedna; u dojenčadi (mlađe od 6 mjeseci): smanjenje doze ne smije biti veće od 7 mg/kg dva puta dnevno svaka dva tjedna).
One tablet of Keppra 500 mg contains 500 mg of levetiracetam. 
Jedna tableta Keppre 500 mg sadrži 500 mg levetiracetama.
The administration of levetiracetam to patients with renal impairment may require dose adjustment. 
U bolesnika s oštećenjem bubrega može biti potrebno prilagođavanje dozelevetiracetama.
Children and adolescents • Keppra is not indicated in children and adolescents below 16 years on it's own (monotherapy) 
• U djece i adolescenata mlađih od 16 godina Keppra se ne primjenjuje samostalno
If levetiracetam has to be discontinued it is recommended to withdraw it gradually (e.g. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in infants older than 6 months, children and adolescents weighting less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks; in infants (less than 6 months): dose decrease should not exceed 7 mg/kg twice daily every two weeks). 
Ako treba prekinuti liječenje levetiracetamom, preporučuje se postupni prekid (npr. u odraslih i adolescenata tjelesne težine veče od 50 kg: smanjenje za 500 mg dva puta na dan svaka dva do četiri tjedna; u dojenčadi starije od 6 mjeseci, djece i adolescenata tjelesne težine manje od 50 kg: smanjenje doze ne smije biti veće od 10 mg/kg dva puta na dan svaka dva tjedna; u dojenčadi (mlađe od 6 mjeseci): smanjenje doze ne smije biti veće od 7 mg/kg dva puta dnevno svaka dva tjedna).
Blue, 13mm oblong, scored and debossed with the code “ucb” and “250” on one side. 
Plava, duguljasta tableta od 13 mm s razdjelnom crtom i utisnutim oznakama „ucb” i „250“ na jednoj strani.
Keppra 100 mg/ml oral solution 
NAZIV LIJEKA Keppra 100 mg/ml oralna otopina
300 ml oral solution 
OBLIK I SADRŽAJ 300 ml oralna otopina
One tablet of Keppra 250 mg contains 250 mg of levetiracetam. 
Jedna tableta Keppre 250 mg sadrži 250 mg levetiracetama.
CLcr (ml/min/1.73 m 2) = ---------------------------- x 1.73 BSA subject (m 
CLcr (ml/min) CLcr (ml/min/1.73 m2) = ------------------------------ x 1,73 PT bolesnika (m2)
One tablet of Keppra 750 mg contains 750 mg of levetiracetam. 
Jedna tableta Keppre 750 mg sadrži 750 mg levetiracetama.
• as an add-on to other antiepileptic medicines to treat: ▪ partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age ▪ myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy ▪ primary generalised tonic-clonic seizures(major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause). 
• kao dodatna terapija uz druge antiepileptike u liječenju: ▪ parcijalnih napadaja sa sekundarnom generalizacijom ili bez nje u odraslih, adolescenata, djece i dojenčadi od prvog mjeseca života ▪ miokloničkih napadaja (kratki, iznenadni trzaji mišića ili skupine mišića) u odraslih i adolescenata starijih od 12. godine života s juvenilnom miokloničkom epilepsijom ▪ primarno generaliziranih toničko-kloničkih napadaja (veliki napadaji, uključujući gubitak svijesti) u odraslih i adolescenata starijih od 12. godine života s idiopatskom generaliziranom epilepsijom (oblik epilepsije za koji se smatra da je genetski uvjetovan).
White, 19 mm oblong, scored and debossed with the code “ucb” and “1000” on one side. 
Bijela, duguljasta tableta od 19 mm s razdjelnom crtom i utisnutim oznakama „ucb” i „1000“ na jednoj strani.
Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with Keppra overdoses. 
Kod predoziranja Keppre primijećena je somnolencija, agitacija, agresivnost, smanjena razina svijesti, depresija disanja i koma.
Keppra 500 mg film-coated tablets are yellow, 16 mm oblong, scored and debossed with the code “ucb” and “500” on one side. 
Keppra 500 mg filmom obložene tablete su žute, duguljaste, od 16 mm s razdjelnom crtom i utisnutim oznakama „ucb“ i „500“ na jednoj strani.
Orange, 18 mm oblong, scored and debossed with the code “ucb” and “750” on one side. 
Narančasta, duguljasta tableta od 18 mm s razdjelnom crtom i utisnutim oznakama „ucb” i „750“ na jednoj strani.
Citric acid monohydrate Methyl parahydroxybenzoate (E218) Propyl parahydroxybenzoate (E216) Ammonium glycyrrhizate Glycerol (E422) 
6.1 Popis pomoćnih tvari natrijev citrat citratna kiselina hidrat metilparahidroksibenzoat (E218) propilparahidroksibenzoat (E216) amonijev glicirizat glicerol (E422) maltitol, tekući (E965) acesulfamkalij (E950) aroma grožđa voda, pročišćena
Dosing adjustment for adult and adolescents patients weighing more than 50 kg with impaired renal function: 
Prilagođavanje doze za odrasle bolesnike i adolescente tjelesne težine veće od 50 kg s oštećenom bubrežnom funkcijom:
Children 25 kg or less should preferably start the treatment with Keppra 100 mg/ml oral solution. 
1500 mg dva puta na dan (1) U djece od 25 kg ili manje liječenje je najbolje započeti Keppra 100 mg/ml oralnom otopinom.
Yellow, 16 mm oblong, scored and debossed with the code “ucb” and “500” on one side. 
Žuta, duguljasta tableta od 16 mm s razdjelnom crtom i utisnutim oznakama „ucb” i „500“ na jednoj strani.
Do not use this medicine after the expiry date stated on the cardboard box and bottle after EXP: The expiry date refers to the last day of the month. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i boci iza oznake „Rok valjanosti“ ili „EXP:“.
7 to 14 mg/kg (0.07 to 0.14 ml/kg) once daily 
7 do 14 mg/kg (0,07 do 0,14 ml/kg) jedanput na dan
The safety and efficacy of Keppra in children and adolescents below 16 years as monotherapy treatment have not been established. 
Kod monoterapije u djece i adolescenata mlađih od 16 godina sigurnost i djelotvornost Keppre nije dokazana.
300 ml amber glass bottle (type III) with a white child resistant closure (polypropylene) in a cardboard box also containing a 10 ml graduated oral syringe (polypropylene, polyethylene) and an adaptor for the syringe (polyethylene). 
Smeđa staklena boca od 300 ml (staklo tip III) s bijelim sigurnosnim zatvaračem za djecu (polipropilen) u kartonskoj kutiji koja također sadrži graduiranu plastičnu štrcaljku za usta od 10 ml (polipropilen, polietilen) i nastavak za štrcaljku (polietilen).
Keppra 750 mg 
16. PODACI NA BRAILLEOVOM PISMU Keppra 750 mg
Each film-coated tablet contains 1,000 mg levetiracetam. 
TVARI Jedna filmom obložena tableta sadrži 1000 mg levetiracetama.
Dosing adjustment for infants, children and adolescents patients weighing less than 50 kg with impaired renal function: 
Prilagođavanje doze kod dojenčadi, djece i adolescenata s manje od 50 kg tjelesne težine s oštećenom bubrežnom funkcijom:
Linear and dose proportional increases were observed for peak plasma concentration and area under the curve. 
Za vršne koncentracije u plazmi i površinu ispod krivulje primijećena su linearna povećanja i proporcionalna s dozom.
EU/1/00/146/018 80 tablets 
EU/1/00/146/018 80 tableta
• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. 
• u liječenju miokloničkih napadaja u odraslih i adolescenata od 12. godine života s juvenilnom miokloničkom epilepsijom
Keppra 1000 mg film-coated tablets Levetiracetam 
Keppra 1000 mg filmom obložene tablete levetiracetam
EU/1/00/146/019 100 tablets 
EU/1/00/146/019 100 tableta
EU/1/00/146/022 30 tablets 
EU/1/00/146/022 30 tableta
150 ml amber glass bottle (type III) with a white child resistant closure (polypropylene) in a cardboard box also containing a 1 ml graduated oral syringe (polypropylene, polyethylene) and an adaptor for the syringe (polyethylene). 
Smeđa staklena boca od 150 ml (staklo tip III) s bijelim sigurnosnim zatvaračem za djecu (polipropilen) u kartonskoj kutiji koja također sadrži graduiranu plastičnu štrcaljku od 1 ml za usta (polipropilen, polietilen) i nastavak za štrcaljku (polietilen).
150 ml amber glass bottle (type III) with a white child resistant closure (polypropylene) in a cardboard box also containing a 3 ml graduated oral syringe (polypropylene, polyethylene) and an adaptor for the syringe (polyethylene). 
Smeđa staklena boca od 150 ml (staklo tip III) s bijelim sigurnosnim zatvaračem za djecu (polipropilen) u kartonskoj kutiji koja također sadrži graduiranu plastičnu štrcaljku za usta od 3 ml (polipropilen, polietilen) i nastavak za štrcaljku (polietilen).
EU/1/00/146/015 30 tablets 
EU/1/00/146/015 30 tableta
Keppra 250 mg 
16. PODACI NA BRAILLEOVOM PISMU Keppra 250 mg
Keppra oral solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets. 
(1) Za doze ispod 250 mg, za doze koje nisu višekratnici od 250 mg, odnosno kada preporučeno doziranje ne može biti postignuto uzimanjem većeg broja tableta i kod bolesnika koji ne mogu gutati tablete treba koristiti Keppra oralnu otopinu.
EU/1/00/146/025 100 tablets 
EU/1/00/146/025 100 tableta
EU/1/00/146/017 60 tablets 
EU/1/00/146/017 60 tableta
Keppra 1000 mg 
16. PODACI NA BRAILLEOVOM PISMU Keppra 1000 mg
EU/1/00/146/024 60 tablets 
EU/1/00/146/024 60 tableta
EU/1/00/146/023 50 tablets 
EU/1/00/146/023 50 tableta
EU/1/00/146/006 EU/1/00/146/007 EU/1/00/146/008 EU/1/00/146/009 EU/1/00/146/010 EU/1/00/146/011 EU/1/00/146/012 EU/1/00/146/013 EU/1/00/146/035 
EU/1/00/146/008 EU/1/00/146/009 EU/1/00/146/010 EU/1/00/146/011 EU/1/00/146/012 EU/1/00/146/013 EU/1/00/146/035
Keppra 500 mg 
16. PODACI NA BRAILLEOVOM PISMU Keppra 500 mg
Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study, which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening). 
Djelotvornost levetiracetama dokazana je u dvostruko slijepoj i placebom kontroliranoj studiji u trajanju od 24 tjedna, koja je uključivala odrasle, adolescente i ograničeni broj djece s idiopatskom generaliziranom epilepsijom s primarno generaliziranim toničko-kloničkim (PGTK) napadajima kod različitih sindroma (juvenilna mioklonična epilepsija, epilepsija s apsansima dječje i juvenilne dobi ili epilepsija s grand mal napadajima kod buđenja).
Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. 
Dodatna terapija u liječenju parcijalnih napadaja sa sekundarnom generalizacijom ili bez nje u odraslih, adolescenata i djece od navršene 4. godine života s epilepsijom.
EU/1/00/146/016 50 tablets 
EU/1/00/146/016 50 tableta
Starting dose: 7 mg/kg twice daily 
Početna doza: 7 mg/kg dva puta na dan
MARKETING AUTHORISATION NUMBER(S) EU/1/00/146/014 20 tablets 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/00/146/032
Keppra 750 mg film-coated tablets Levetiracetam 
Keppra 750 mg filmom obložene tablete levetiracetam
• in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. 
• u liječenju parcijalnih napadaja sa sekundarnom generalizacijom ili bez nje u odraslih, adolescenata i djece od 4. godine života s epilepsijom.
What Keppra looks like and contents of the pack Keppra 100 mg/ml oral solution is a clear liquid. 
Keppra 100 mg/ml oralna otopina je bistra tekućina.
Maximum dose: 21 mg/kg twice daily 
Najveća doza: 21 mg/kg dva puta na dan
200 mg (2 ml) twice daily 600 mg (6 ml) twice daily 
600 mg (6 ml) dva puta na dan
What Keppra looks like and contents of the pack Keppra 250 mg film-coated tablets are blue, 13 mm oblong, scored and debossed with the code “ucb” and “250” on one side. 
Keppra 250 mg filmom obložene tablete su plave, duguljaste, od 13 mm s razdjelnom crtom i utisnutim oznakama „ucb“ i „250“ na jednoj strani.